A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults

Summary

Part A of the study will test the safety, the amount of drug in the body, and effects of the drug in the body after multiple doses. This will be conducted in healthy overweight adults. Part B of the study will test the effects of multiple doses of the investigational drug on the amount of midazolam, an approved drug, in healthy adults.

Conditions

• Healthy

Interventions

DRUG

PF-06282999

Tablet, 10 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 30 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 100 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 250 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 or 12 hours, 14 days

DRUG

midazolam

Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

DRUG

PF-06282999

Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days

DRUG

midazolam

Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

DRUG

PF-06282999

Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2012-10-31

Primary Completion

2013-05-31

Completion

2013-05-31

Countries

• Belgium

Study Locations